Table 1.

Characteristics of study participants

Variables	Total	Nonobese	Obese
N	38	18	20
Age, yr	34 ± 9	34 ± 10	34 ± 9
BMI, kg/m2	28.6 ± 5.9	23.0 ± 1.8	33.5 ± 3.2‡
Fasting glucose, mg/dl	91 ± 10	86 ± 6	96 ± 11†
Fasting insulin, μIU/ml	7 ± 4	5 ± 2	9 ± 4‡
Postprandial glucose, mg/dl	108 ± 10	104 ± 8	111 ± 10*
Postprandial insulin, μIU/ml	19 ± 14	11 ± 7	25 ± 15‡
HOMA-IR	1.7 ± 1.0	1.0 ± 0.4	2.2 ± 0.9‡
Total cholesterol, mg/dl	180 ± 35	176 ± 38	183 ± 33
HDL-cholesterol, mg/dl	58 ± 17	64 ± 18	53 ± 14
Triglyceride, mg/dl	89 ± 53	75 ± 32	101 ± 64
Body fat, %	33.9 ± 11.2	25.5 ± 8.7	41.0 ± 7.6‡
Total body fat, kg	28.4 ± 12.3	16.9 ± 5.0	38.2 ± 6.7‡
FFM, kg	53.4 ± 11.4	50.8 ± 12.0	55.7 ± 10.6
UBSQ fat, kg	15.5 ± 7.2	9.0 ± 3.1	20.9 ± 4.8‡
LBSQ fat, kg	10.2 ± 4.3	6.6 ± 2.0	13.4 ± 3.0‡
Visceral fat, kg	2.7 ± 2.1	1.3 ± 0.7	4.0 ± 2.1‡
Plasma palmitate, μmol/l (0–90 min)	30 ± 21	26 ± 12	34 ± 27
Plasma palmitate turnover, μmol/min (0–90 min)	70 ± 38	65 ± 31	74 ± 43
Plasma [U-13C]palmitate enrichment (0–90 min)	0.064 ± 0.035	0.064 ± 0.035	0.064 ± 0.036
Plasma palmitate, μmol/l (150–330 min)	32 ± 24	28 ± 19	35 ± 27
Plasma palmitate turnover, μmol/min (150–330 min)	63 ± 36	59 ± 28	66 ± 43
Plasma [U-13C]palmitate enrichment (150–330 min)	0.072 ± 0.040	0.072 ± 0.037	0.072 ± 0.042

Data are shown as means ± SD. Postprandial insulin is an average concentration of plasma insulin during the postprandial condition. For the entire group, plasma palmitate enrichment increased significantly from the time interval 0–90 min to 150–330 min, P = 0.012. BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; FFM, fat-free mass; HDL, high-density lipoprotein; LBSQ, lower body subcutaneous; UBSQ, upper body subcutaneous.

^*vs. nonobese, P < 0.05;

^†vs. nonobese, P < 0.01,

^‡vs. nonobese, P < 0.001.